At Protagen, we are dedicated to the development of powerful diagnostic tools that aid successful therapeutic development and better treatment strategies for some of the most severe autoimmune diseases. Utilizing a personalized medicine approach, our powerful multi-marker assay technology SeroTag enables differential diagnosis and patient stratification in some of the most relevant diseases, such as Rheumatoid Arthritis, Systemic Lupus Erythematosus and Multiple Sclerosis. With our high-throughput disease and treatment marker development engine (SeroTag), we are uniquely positioned to develop innovative autoimmune diagnostics.This is evidenced by our broad development portfolio of novel diagnostic tests, secured by strong IP coverage and validated by proof-of concept studies in thousands of clinical samples.

The identification of patient subgroups has become essential for developing new medicines that work effectively for each individual. Here, Protagen has developed the NavigAID concept. The first product NavigAID SLE separates and defines patient subgroups in SLE, overcoming patient heterogeneity and enabling new approaches for successful drug development together with our partners in Pharma and Biotech. In July 2015 we have launched NavigAID SSc.

We are committed to providing our customers and collaborators with exceedingly high levels of service, supporting them throughout the diagnostic test development and implementation process, and providing proactive and expert guidance.